These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 10100282

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats.
    Hirano T, Mamo JC, Nagano S, Sugisaki T.
    Nephron; 1991; 58(1):95-100. PubMed ID: 1857487
    [Abstract] [Full Text] [Related]

  • 3. Effect of probucol on hyperlipidemia in patients with nephrotic syndrome.
    Iida H, Izumino K, Asaka M, Fujita M, Nishino A, Sasayama S.
    Nephron; 1987; 47(4):280-3. PubMed ID: 3696330
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Should hyperlipidemia in children with the nephrotic syndrome be treated?
    Querfeld U.
    Pediatr Nephrol; 1999 Jan; 13(1):77-84. PubMed ID: 10100296
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis.
    Hirano T, Morohoshi T.
    Nephron; 1992 Jan; 60(4):443-7. PubMed ID: 1584321
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lysophosphatidylcholine molecular species in low density lipoprotein and high density lipoprotein in alloxan-induced diabetic rats: effect of probucol.
    Shi A, Yoshinari M, Iino K, Wakisaka M, Iwase M, Fujishima M.
    Exp Clin Endocrinol Diabetes; 1999 Jan; 107(6):337-42. PubMed ID: 10543409
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Effect of probucol on cardiac electrophysiology in anginal patients with hyperlipidemia and diabetes mellitus type II].
    Anikin VV, Savin VV, Lupanov VP, Razygraev RA.
    Ter Arkh; 2000 Jan; 72(8):28-30. PubMed ID: 11019422
    [Abstract] [Full Text] [Related]

  • 13. Characteristics of lipid metabolism under different urinary protein excretion in children with primary nephrotic syndrome.
    Hu P, Lu L, Hu B, Du PF.
    Scand J Clin Lab Invest; 2009 Jan; 69(6):680-6. PubMed ID: 19468931
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Post-marketing surveillance of probucol (Sinlestal) in Japan.
    Kosasayama A, Yoshida M, Okada S.
    Artery; 1992 Jan; 19(3):147-61. PubMed ID: 1637256
    [Abstract] [Full Text] [Related]

  • 19. Long-term effect of lovastatin on lipoprotein profile in patients with primary nephrotic syndrome.
    Prata MM, Nogueira AC, Pinto JR, Correia AM, Vicente O, Rodrigues MC, Miguel MJ.
    Clin Nephrol; 1994 May; 41(5):277-83. PubMed ID: 8050207
    [Abstract] [Full Text] [Related]

  • 20. Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study.
    Haas M, Mayer G, Wirnsberger G, Holzer H, Ratschek M, Neyer U, Neuweiler J, Kramar R, Schneider B, Breiteneder-Geleff S, Regele HM, Hörl WH, Kerjaschki D.
    Wien Klin Wochenschr; 2002 Feb 28; 114(4):143-7. PubMed ID: 12060980
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.